Thomas Patrick Kelly

Insider Reports History

Location
Waltham, MA
Signature
/s/ Nathaniel Adams, Attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Thomas Patrick Kelly:

Form 4 holding Chief Financial Officer

Deciphera Pharmaceuticals, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
$0
Report date
11 Jun 2024
Price
$10.58
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Xenon Pharmaceuticals Inc.

Security class
No securities are beneficially owned.
Shares / value
0
Estimated value
Report date
15 Oct 2025
Price
Ownership
Direct

Insider Reports Filed by Thomas Patrick Kelly

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .